National & Kapodistrian University of Athens, Medical School, Department of Pharmacology, Athens, Greece.
Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):989-99. doi: 10.1517/17425255.2013.794786. Epub 2013 May 4.
Geriatric depression is a heterogeneous disorder with a complex genetic background. Current first-line treatment of depression is associated with a lower therapeutic outcome in aged depressed patients, when compared to younger subjects. Research which has explored this inadequate response has highlighted several factors which have come into play with the pharmacogenetics of antidepressants in the elderly being a particular area of interest.
The authors perform a critical review of the English language articles from PubMed using search terms such as late-life/geriatric depression, antidepressants, pharmacogenetics, pharmacogenomics, pharmacokinetic, genetic, genotype, remission, therapy, treatment and polymorphism.
The emerging clinical and pharmacogenetic data are slowly unveiling the importance of the genome - age interaction in antidepressant response. This data introduces a critical new parameter in personalized medicine. A profound analysis of the age factor in the pharmacogenetics of antidepressant response is imperative, in order to elucidate the clinical significance of these findings and thereby improve patient treatment in the elderly.
老年抑郁症是一种具有复杂遗传背景的异质性疾病。与年轻患者相比，目前针对抑郁症的一线治疗方法在老年抑郁症患者中的治疗效果较低。对这种治疗反应不足的研究强调了几个因素，其中老年人抗抑郁药的药物遗传学是一个特别感兴趣的领域。
作者使用“老年/老年抑郁症、抗抑郁药、药物遗传学、药物基因组学、药代动力学、遗传、基因型、缓解、治疗、治疗和多态性”等搜索词，从 PubMed 中进行了英语文章的批判性综述。
正在出现的临床和药物遗传学数据正在慢慢揭示基因组与年龄相互作用在抗抑郁反应中的重要性。这些数据为个性化医学引入了一个关键的新参数。深入分析抗抑郁药反应的药物遗传学中的年龄因素至关重要，以便阐明这些发现的临床意义，从而改善老年人的患者治疗效果。
